 |
|
|
| |
SAFETY AND EFFICACY OF ELBASVIR/GRAZOPREVIR IN ASIAN PARTICIPANTS WITH HEPATITIS C VIRUS INFECTION: AN INTEGRATED ANALYSIS OF DATA FROM 11 PHASE 2/3 TRIALS
|
| |
| |
Reported by Jules Levin
APASL 2018 March 14-18 New Delhi
Lai Wei1; Hiromitsu Kumada2; Ponni V. Perumalswami3; Tawesak Tanwandee4; Wendy Cheng5; Jeong Heo6; Pin-Nan Cheng7; Peggy Hwang8; Sheng Mei Mu9; Xu Min Zhao9; Michael Robertson8; Barbara Haber8; Rohit Talwani8
1Peking University People's Hospital, Beijing, China; 2Hepatology, Toranomon Hospital, Tokyo, Japan; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Siriraj Hospital, Bangkok, Thailand; 5Royal Perth Hospital, Perth, WA, Australia; 6College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, South Korea; 7National Cheng Kung University, Tainan, Taiwan; 8Merck & Co., Inc., Kenilworth, NJ, USA; 9Merck, Sharp & Dohme, Beijing, China
|
| |
|
|
|
|
|
